Clinical Trial Update: E3-Hormone Refractory Prostrate Cancer Taxotere Combination [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a Taxotere (docetaxel) combination for hormone-refractory metastatic prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-refractory Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: Sanofi | Conditions: Prostate Cancer, Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2011-05-24